BNP Paribas Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

BNP Paribas Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-86,097	Closed	-$6.97M	–	982
2018 Q1	$6.97M	Sell	86,097 -139,415	-62%	-$11.3M	0.06%	414
2017 Q4	$17.8M	Buy	225,512 +79,915	+55%	+$6.64M	0.15%	187
2017 Q3	$13.4M	Buy	+145,597	New	+$14M	0.11%	240

Other funds holding CBPO

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Asset Management's CBPO Position: Q2 2018 in Review

BNP Paribas Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2018, closing a stake of 86,097 shares — an estimated $6.97M sold.

BNP Paribas Asset Management first reported a position in CBPO in Q3 2017 and held it in 3 quarters. The position peaked at $17.8M in Q4 2017. 91 funds tracked by Wall St. Rank hold CBPO as of Q2 2018.

BNP Paribas Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2018 after selling out during the quarter.
BNP Paribas Asset Management sold 86,097 China Biologic Products Holdings, Inc. shares in Q2 2018, an estimated $6.97M.
BNP Paribas Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2017 and held it in 3 quarters.
BNP Paribas Asset Management's China Biologic Products Holdings, Inc. position peaked at $17.8M in Q4 2017.
91 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2018.

Based on BNP Paribas Asset Management's 13F filing for Q2 2018, filed 1 Aug 2018.